Unstable mitochondrial DNA (mtDNA) mutations in hepatocellular carcinoma (HCC) were studied using a novel sequencing platform called single-cell capture-based mtDNA sequencing (sc-CAMS). This method allowed researchers to analyze mtDNA mutations at single-cell resolution, providing detailed insights into tumor heterogeneity.
Unstable mitochondrial DNA (mtDNA) mutations in hepatocellular carcinoma (HCC) were studied using a novel sequencing platform called single-cell capture-based mtDNA sequencing (sc-CAMS). This method allowed researchers to analyze mtDNA mutations at single-cell resolution, providing detailed insights into tumor heterogeneity. In the study, 1,641 single cells from 11 HCC patients and 528 cells from two xenograft mouse models were analyzed, revealing two types of mtDNA mutations: stable mutations (consistent heteroplasmy across cells) and unstable mutations (high variability in heteroplasmy among cells).
Unstable mtDNA mutations were strongly linked to intratumor heterogeneity (ITH), a hallmark of aggressive tumors. Tumors with high levels of unstable mutations exhibited proliferative and aggressive clinical features. These mutations evolved bidirectionally during tumor progression, undergoing both positive selection (expansion) and negative selection (elimination), showcasing the dynamic nature of tumor evolution. Through evolutionary reconstruction, researchers demonstrated that HCC follows both linear and branched progression models, indicating multiple evolutionary paths within the same tumor.
The study also visualized the spatiotemporal evolution of mtDNA mutations in patient-derived xenografts and multifocal tumor regions, showing how these mutations influence metabolic homeostasis, tumor evolution, and therapeutic resistance. Unstable mtDNA mutations could serve as biomarkers for tumor prognosis, stratification, and targeted therapies in HCC.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.